Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity.
By Margaret E. E. Jones, A. Thorburn, K. Britt, Kylie N. Hewitt, N. Wreford, J. Proietto, Orhan K Öz, B. Leury, K. Robertson, Shenggen Yao and 1 more. Proceedings of the National Academy of Sciences of the United States of America, 2000
764 citations recorded by the source corpus.
Subfields: Endocrine and Autonomic Systems, Epidemiology, Genetics
View Paper: https://www.semanticscholar.org/paper/29e733edf1e12f56b942b4d38335ce7e489ab2aa
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrine and Autonomic Systems
In Epidemiology
Citations in the corpus
- AMPK in Health and Disease. (2009, background): “Since the constitutively active AMPK fragment 1 (1-312) is not activated by the PT1 compound, it is proposed that PT1 acts by reversing the autoinhibition of the AIS (313-335).”
- The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy (2017, background): “The ablation of aromatase has also been demonstrated to be associated with increased adiposity [101] and progressive insulin resistance [102], which are significant factors in the development of cardiovascular diseases including atherosclerosis and diabetic cardiomyopathy.”